FDA supplemental approval: Hydrocodone Bitartrate AND Acetaminophen (REMS)

AI Summary

The FDA approved a supplemental ANDA for hydrocodone bitartrate 5 mg plus acetaminophen 300 mg tablets under REMS requirements on 18 June 2026. This regulatory action confirms eligibility for marketing of a fixed-dose opioid–nonopioid analgesic combination but does not contain clinical trial data, efficacy claims, or comparative safety evidence.

Plain-language summary

FDA supplemental approval of a hydrocodone-acetaminophen combination tablet under REMS requirements; a regulatory action, not a clinical evidence base.

Reported figures

Quoted from the source exactly as published.

Clinical bottom line

This record confirms regulatory authorization to market a specific opioid–acetaminophen formulation. It does not establish clinical efficacy, safety profile, or comparative advantage over existing products; prescribers and patients should consult published clinical evidence and prescribing information for safety and efficacy data.

Caveats

• This is a regulatory record, not a clinical trial. It contains no efficacy data, safety outcomes, comparative benefit data, or trial results.
• REMS approval indicates risk mitigation requirements but does not specify the content of those requirements in this record.
• No information on prior clinical studies, evidence supporting approval, or postmarketing commitments is provided in this record.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.